admin – Page 6827 – Get News Story

Generalized Anxiety Disorder Market is Predicted to Exhibit Remarkable Growth During the Forecast Period (2023-2032), Analyzes DelveInsight | Takeda, Sumitomo Pharma, Astrazeneca, Natreon, Pfizer

The Generalized Anxiety Disorder Market size was valued approximately USD 1.54 billion in 2022 and the report offers an in-depth understanding of the Generalized Anxiety Disorder, historical and forecasted epidemiology as well as the Generalized Anxiety Disorder market trends in the 7MM.

DelveInsight’s “Generalized Anxiety Disorder Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Generalized Anxiety Disorder, historical and forecasted epidemiology as well as the Generalized Anxiety Disorder market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Generalized Anxiety Disorder market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Generalized Anxiety Disorder Market Forecast

Some of the key facts of the Generalized Anxiety Disorder Market Report:

The Generalized Anxiety Disorder market size was valued approximately USD 1.54 billion in 2022 and is anticipated to grow with a significant CAGR during the study period (2019-2032)
In March 2024, Numinus Wellness Inc. (“Numinus” or the “Company”) (TSX: NUMI) (OTCQX: NUMIF), a mental health care company dedicated to advancing traditional and innovative behavioral health treatments, congratulates Mind Medicine (“MindMed” NASDAQ: MNMD, Cboe Canada: MMED) on the encouraging results obtained from its Phase 2b clinical trial of MM120 (lysergide d-tartrate) for generalized anxiety disorder (“GAD”). The trial revealed that four weeks after a single 100-microgram dose of MM120, 48 percent of participants achieved remission, showing no clinically significant anxiety, and 65 percent displayed clinically meaningful improvement. Given the initial clinical findings from the Phase 2b trial and the considerable unmet medical need in GAD treatment, the U.S. Food & Drug Administration (“FDA”) has classified MM120 for GAD as a breakthrough therapy.
In February 2024, Incannex Healthcare Inc. (Nasdaq: IXHL), a prominent biotechnology company specializing in cannabinoid and psychedelic medicine, is delighted to report favorable top-line findings from its Phase 2 Psi-GAD1 clinical trial investigating psilocybin for generalized anxiety disorder (GAD). The study successfully achieved its primary objective, showing a significant clinical benefit in the psilocybin treatment group compared to the placebo group.
In 2022, there were 16,158,749 diagnosed prevalent cases of GAD in the 7MM overall. The United States was involved in almost 52% of these cases
In France, there were 373,406 severe cases of Generalized Anxiety Disorder in 2022, 515,601 moderate cases, and 267,049 light ones. According to assessments made by DelveInsight’s analysts, incidences of GAD in adults with varying degrees of severity are expected to rise in the years to come
Germany has the greatest frequency of Generalized Anxiety Disorder among the EU-4 nations, with an estimated 1,450,264 cases in 2022, and the number of cases is projected to continue rising by 2032
In Germany, there were 958,624 cases of Generalized Anxiety Disorder in females and 491,639 cases in males in 2022. DelveInsight experts’ assessments indicate that the general prevalence in both genders is likely to rise in the upcoming years
Key Generalized Anxiety Disorder Companies: Fabre-Kramer Pharmaceuticals, Mind Med, Sunovion, ChemRar Research, Biohaven Pharma, Forest Laboratories, Sumitomo Pharma, Eli Lilly and Company, Engrail Therapeutics INC, H. Lundbeck A/S, Takeda, Sumitomo Pharma, Astrazeneca, Natreon, Inc., Pfizer, Bristol-Myers Squibb, and others
Key Generalized Anxiety Disorder Therapies: EXXUA, MM-120, Ulotaront(SEP363856), CD-008-0045, Troriluzole, Vilazodone, SEP-363856, Duloxetine, ENX-102, Escitalopram, Vortioxetine, eszopiclone, Lu AA21004, Quetiapine fumarate, Sensoril®, Pregabalin, pexacerfont, and others
The Generalized Anxiety Disorder epidemiology based on gender analyzed that Generalized anxiety disorder (GAD) is more prevalent in females than males
The Generalized Anxiety Disorder market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Generalized Anxiety Disorder pipeline products will significantly revolutionize the Generalized Anxiety Disorder market dynamics.

Generalized Anxiety Disorder Overview

Generalized Anxiety Disorder (GAD) is a mental health condition characterized by persistent and excessive worry or anxiety about various aspects of life, such as work, relationships, health, or daily activities. Individuals with GAD often find it challenging to control their worry, which can interfere with their ability to function normally and lead to significant distress or impairment in social, occupational, or other important areas of life.

Get a Free sample for the Generalized Anxiety Disorder Market Report:

https://www.delveinsight.com/report-store/generalized-anxiety-disorder-gad-market

Generalized Anxiety Disorder Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Generalized Anxiety Disorder Epidemiology Segmentation:

The Generalized Anxiety Disorder market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

Total Prevalence of Generalized Anxiety Disorder
Prevalent Cases of Generalized Anxiety Disorder by severity
Gender-specific Prevalence of Generalized Anxiety Disorder
Diagnosed Cases of Episodic and Chronic Generalized Anxiety Disorder

Download the report to understand which factors are driving Generalized Anxiety Disorder epidemiology trends @ Generalized Anxiety Disorder Epidemiology Forecast

Generalized Anxiety Disorder Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Generalized Anxiety Disorder market or expected to get launched during the study period. The analysis covers Generalized Anxiety Disorder market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Generalized Anxiety Disorder Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Generalized Anxiety Disorder Therapies and Key Companies

EXXUA: Fabre-Kramer Pharmaceuticals
MM-120: Mind Med
Ulotaront(SEP363856): Sunovion
CD-008-0045: ChemRar Research
Troriluzole: Biohaven Pharma
Vilazodone: Forest Laboratories
SEP-363856: Sumitomo Pharma
Duloxetine: Eli Lilly and Company
ENX-102: Engrail Therapeutics INC
Escitalopram: H. Lundbeck A/S
Vortioxetine: Takeda
eszopiclone: Sumitomo Pharma
Lu AA21004: H. Lundbeck A/S
Quetiapine fumarate: Astrazeneca
Sensoril®: Natreon, Inc.
Pregabalin: Pfizer
pexacerfont: Bristol-Myers Squibb

Discover more about therapies set to grab major Generalized Anxiety Disorder market share @ Generalized Anxiety Disorder Treatment Market

Generalized Anxiety Disorder Market Strengths

A series of diagnostic guidelines, each building on the prior, have presented clear diagnostic criteria and led to a standardization of reporting in the field, increasing the diagnostic and treatment rate.
Increased diagnosis rates in various countries is directly associated with the growing geriatric population and fast-paced lifestyle among adults.
Research examining novel pharmacotherapies and refining psychosocial approaches for the treatment of GAD is underway and promises to provide additional treatment

Generalized Anxiety Disorder Market Opportunities

There is an urgent requirement for therapies that are safer and have rapid action.
Despite the significant unmet needs in the treatment, only a few players are actively involved in the therapy area, thus, the market offers opportunities to players to bring novel treatments that could shift the treatment paradigm
Epidemiologic studies may help in planning treatment and prevention programs, and may also help us better understand the etiology of these disorders.

Scope of the Generalized Anxiety Disorder Market Report

Study Period: 2019–2032
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Key Generalized Anxiety Disorder Companies: Fabre-Kramer Pharmaceuticals, Mind Med, Sunovion, ChemRar Research, Biohaven Pharma, Forest Laboratories, Sumitomo Pharma, Eli Lilly and Company, Engrail Therapeutics INC, H. Lundbeck A/S, Takeda, Sumitomo Pharma, Astrazeneca, Natreon, Inc., Pfizer, Bristol-Myers Squibb, and others
Key Generalized Anxiety Disorder Therapies: EXXUA, MM-120, Ulotaront(SEP363856), CD-008-0045, Troriluzole, Vilazodone, SEP-363856, Duloxetine, ENX-102, Escitalopram, Vortioxetine, eszopiclone, Lu AA21004, Quetiapine fumarate, Sensoril®, Pregabalin, pexacerfont, and others
Generalized Anxiety Disorder Therapeutic Assessment: Generalized Anxiety Disorder current marketed and Generalized Anxiety Disorder emerging therapies
Generalized Anxiety Disorder Market Dynamics: Generalized Anxiety Disorder market drivers and Generalized Anxiety Disorder market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
Generalized Anxiety Disorder Unmet Needs, KOL’s views, Analyst’s views, Generalized Anxiety Disorder Market Access and Reimbursement

To know more about Generalized Anxiety Disorder companies working in the treatment market, visit @ Generalized Anxiety Disorder Clinical Trials and Therapeutic Assessment

Table of Contents

1. Generalized Anxiety Disorder Market Report Introduction

2. Executive Summary for Generalized Anxiety Disorder

3. SWOT analysis of Generalized Anxiety Disorder

4. Generalized Anxiety Disorder Patient Share (%) Overview at a Glance

5. Generalized Anxiety Disorder Market Overview at a Glance

6. Generalized Anxiety Disorder Disease Background and Overview

7. Generalized Anxiety Disorder Epidemiology and Patient Population

8. Country-Specific Patient Population of Generalized Anxiety Disorder

9. Generalized Anxiety Disorder Current Treatment and Medical Practices

10. Generalized Anxiety Disorder Unmet Needs

11. Generalized Anxiety Disorder Emerging Therapies

12. Generalized Anxiety Disorder Market Outlook

13. Country-Wise Generalized Anxiety Disorder Market Analysis (2019–2032)

14. Generalized Anxiety Disorder Market Access and Reimbursement of Therapies

15. Generalized Anxiety Disorder Market Drivers

16. Generalized Anxiety Disorder Market Barriers

17. Generalized Anxiety Disorder Appendix

18. Generalized Anxiety Disorder Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Generalized Anxiety Disorder Market is Predicted to Exhibit Remarkable Growth During the Forecast Period (2023-2032), Analyzes DelveInsight | Takeda, Sumitomo Pharma, Astrazeneca, Natreon, Pfizer

Allianz Trade Named Best Trade Credit Insurance Company Asia Pacific 2024 at the Global Banking & Finance Awards®

In a remarkable demonstration of industry leadership and commitment to excellence, Allianz Trade in Asia Pacific has been honored with the prestigious title of Best Trade Credit Insurance Company Asia Pacific for the year of 2024 by the Global Banking & Finance Awards®. This year marks the eighth consecutive win for Allianz Trade in this category, further cementing its position as a leader in the trade credit insurance sector.

Wanda Rich, Editor of Global Banking & Finance Review, commented on the award: “Allianz Trade in Asia Pacific continues to set the benchmark for the trade credit insurance industry. Their unyielding dedication to providing unparalleled service, combined with their expansive global network, enables them to offer businesses the highest level of support and communication. It is their ability to anticipate market changes and provide predictive protection through unrivalled global business intelligence that truly sets them apart. This, along with their continuous innovation and investment in technology such as AI for better underwriting decisions, exemplifies why they are once again the deserving recipient of the Best Trade Credit Insurance Company Asia Pacific award for 2024.”

Allianz Trade’s approach to trade credit insurance is built on a foundation of providing best-in-class service to its customers. By prioritizing predictive protection, Allianz Trade delivers exceptional global business intelligence, market knowledge, and industry risk analysis, enabling businesses to navigate and thrive in ever-changing market conditions. The company offers an extensive range of integrated products and services designed to support both the short-term and long-term goals of businesses, thereby improving their financial health and protecting their cash flow.

Paul Flanagan, Regional CEO at Allianz Trade in Asia Pacific, remarks, “Being named to the award for eight straight year is truly an honour, and particularly an auspicious number in the Chinese culture. Our approach to the business is customer-centric, evidenced by our industry-leading NPS scores as well as historically high client retention rates. As for products, our recently launched Allianz Trade pay provides full cover to the entire B2B e-commerce value chain, from trade credit insurance protection, fraud module, digital buyer onboarding solution to instant financing solution through one of our financial institution partners. Through our comprehensive and innovative trade credit solutions, Allianz Trade is committed to facilitate global trade including the rapidly growing B2B e-commerce sector.”

The relevance of trade credit insurance has escalated, particularly with the expectation of rising insolvencies. Allianz Trade’s comprehensive solutions address these growing concerns, ensuring that businesses remain resilient in the face of financial uncertainties.

2024 is also a milestone year for Allianz Trade in Hong Kong as it celebrates 25 years of success in the region. From its modest beginnings as Hermes Credit Underwriters in 1999 to its evolution into the city’s largest private trade credit solutions provider, Allianz Trade in Hong Kong has become a critical hub for operations in the Asia Pacific region. This silver anniversary coincides with its eighth consecutive award win, highlighting a quarter-century of industry leadership and dedication to securing the receivables of its clients worldwide.

The consistent recognition by the Global Banking & Finance Awards® underscores Allianz Trade’s dominant presence in the Asia Pacific region and its unwavering commitment to excellence and innovation in the trade credit insurance industry.

About Global Banking & Finance Review®

Global Banking & Finance Review® is a premier online portal and digital magazine that has become a trusted standard in the banking and finance industry for its comprehensive, independent news centered on the financial sector. Attracting over 7 million page views annually, it serves as a pivotal resource for balanced views and informative insights, catering to a broad audience interested in the global financial community. To further support individuals and businesses, Global Banking & Finance Review initiated Gawdo.com – Get Any Work Done Online, a dynamic online platform providing a comprehensive array of digital media services. From digital marketing to video creation, https://gawdo.com/ serves as a one-stop-shop for digital services catering to diverse needs.

About the Global Banking & Finance Awards®

Celebrating excellence and innovation within the global financial community, the Global Banking & Finance Awards® were established in 2011 to recognize companies of all sizes that are prominent in particular areas of expertise and excellence within the global financial community. These awards are well-known throughout the global banking and financial sectors, reflecting innovation, achievement, strategy, and the progressive and inspirational changes occurring within the financial industry.

For more information, please kindly contact:

Mr. Wanda Rich, Editor
Email: wrich@gbafmag.com
Websites: www.globalbankingandfinance.com
https://Gawdo.com/
https://www.financedigest.com/

Media Contact
Company Name: GBAF Media Publications LLC FZ
Contact Person: Wanda Rich
Email: Send Email
Phone: +1-314-480-6841
Address:Business Center 1, M Floor, The Meydan Hotel Nad Al Sheba
City: Dubai
Country: United Arab Emirates
Website: https://www.globalbankingandfinance.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Allianz Trade Named Best Trade Credit Insurance Company Asia Pacific 2024 at the Global Banking & Finance Awards®

HER2-Negative Breast Cancer Market and Epidemiology 2032: Treatment Market, Therapies, Companies, FDA Approvals, Epidemiology and Forecast by DelveInsight | Genentech, Inc., AstraZeneca, Novartis

The HER2-Negative Breast Cancer Market Forecast report offers an in-depth understanding of the HER2-Negative Breast Cancer, historical and forecasted epidemiology as well as the HER2-Negative Breast Cancer market trends in the 7MM.

DelveInsight’s “HER2-Negative Breast Cancer Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the HER2-Negative Breast Cancer, historical and forecasted epidemiology as well as the HER2-Negative Breast Cancer market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the HER2-Negative Breast Cancer market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; HER2-Negative Breast Cancer Market Forecast

Some of the key facts of the HER2-Negative Breast Cancer Market Report:

The HER2-Negative Breast Cancer market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
In December 2023, Puma Biotechnology, a biopharmaceutical company headquartered in the United States, has introduced the outline for the Phase II PUMA-ALI-1201 clinical trial assessing alisertib for the treatment of patients with metastatic breast cancer who are HER2-negative and hormone receptor-positive. Following discussions with the US Food and Drug Administration (FDA), the company plans to initiate a trial of alisertib combined with endocrine treatment in chemotherapy-naïve breast cancer patients.
The US experienced 253,465 new cases of breast cancer in 2020, according to the Global Cancer Observatory (2020)
According to data from Surveillance, Epidemiology and End Results (SEER, n.d.), the US female population experiences the diagnosis of more than 200,000 new instances of breast cancer each year
According to the Global Cancer Observatory (2020), there were 69,697 new cases of breast cancer in Germany, France, Italy, Spain, and the United Kingdom, respectively, in 2020
Key HER2-Negative Breast Cancer Companies: Genentech, Inc., AstraZeneca, Merck Sharp & Dohme LLC, Gilead Sciences, BeiGene, Eisai Inc., Novartis Pharmaceuticals, Adagene Inc, Jiangsu HengRui Medicine Co., Ltd, Pfizer, Novartis, CytomX Therapeutics, Tyme, Inc, Puma Biotechnology, Inc., G1 Therapeutics, Inc., Context Therapeutics Inc., and others
Key HER2-Negative Breast Cancer Therapies: Paclitaxel, Doxorubicin, AZD9833, Pembrolizumab, TF2 – 68 Ga-IMP-288, BGB-290, Eribulin, Dapagliflozin, ADG106, Famitinib Malate, Talazoparib Tosylate, Letrozole, CX-2009, SM-88, Neratinib, G1T38, Onapristone, and others
The HER2-Negative Breast Cancer epidemiology based on gender analyzed that HER2-negative breast cancer mainly develops in older women
The HER2-Negative Breast Cancer market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage HER2-Negative Breast Cancer pipeline products will significantly revolutionize the HER2-Negative Breast Cancer market dynamics.

HER2-Negative Breast Cancer Overview

HER2-negative breast cancer refers to a subtype of breast cancer that does not overexpress the human epidermal growth factor receptor 2 (HER2) protein. HER2-negative breast cancer accounts for the majority of breast cancer cases and is characterized by the absence of amplification or overexpression of the HER2 gene.

Get a Free sample for the HER2-Negative Breast Cancer Market Report:

https://www.delveinsight.com/report-store/her2-negative-breast-cancer-market

HER2-Negative Breast Cancer Epidemiology

HER2-Negative Breast Cancer Epidemiology Segmentation:

The HER2-Negative Breast Cancer market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

Total Prevalence of HER2-Negative Breast Cancer
Prevalent Cases of HER2-Negative Breast Cancer by severity
Gender-specific Prevalence of HER2-Negative Breast Cancer
Diagnosed Cases of Episodic and Chronic HER2-Negative Breast Cancer

Download the report to understand which factors are driving HER2-Negative Breast Cancer epidemiology trends @ HER2-Negative Breast Cancer Epidemiology Forecast

HER2-Negative Breast Cancer Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the HER2-Negative Breast Cancer market or expected to get launched during the study period. The analysis covers HER2-Negative Breast Cancer market uptake by drugs, patient uptake by therapies, and sales of each drug.

The report also covers the HER2-Negative Breast Cancer Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

HER2-Negative Breast Cancer Therapies and Key Companies

Paclitaxel: Dana-Farber Cancer Institute
Doxorubicin: Genentech, Inc.
AZD9833: AstraZeneca
Pembrolizumab: Merck Sharp & Dohme LLC
TF2 – 68 Ga-IMP-288: Gilead Sciences
BGB-290: BeiGene
Eribulin: Eisai Inc.
Dapagliflozin: Novartis Pharmaceuticals
ADG106: Adagene Inc
Famitinib Malate: Jiangsu HengRui Medicine Co., Ltd
Talazoparib Tosylate: Pfizer
Letrozole: Novartis
CX-2009: CytomX Therapeutics
SM-88: Tyme, Inc
Neratinib: Puma Biotechnology, Inc.
G1T38: G1 Therapeutics, Inc.
Onapristone: Context Therapeutics Inc.

Discover more about therapies set to grab major HER2-Negative Breast Cancer market share @ HER2-Negative Breast Cancer Treatment Market

Scope of the HER2-Negative Breast Cancer Market Report

Study Period: 2019–2032
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Key HER2-Negative Breast Cancer Companies: Genentech, Inc., AstraZeneca, Merck Sharp & Dohme LLC, Gilead Sciences, BeiGene, Eisai Inc., Novartis Pharmaceuticals, Adagene Inc, Jiangsu HengRui Medicine Co., Ltd, Pfizer, Novartis, CytomX Therapeutics, Tyme, Inc, Puma Biotechnology, Inc., G1 Therapeutics, Inc., Context Therapeutics Inc., and others
Key HER2-Negative Breast Cancer Therapies: Paclitaxel, Doxorubicin, AZD9833, Pembrolizumab, TF2 – 68 Ga-IMP-288, BGB-290, Eribulin, Dapagliflozin, ADG106, Famitinib Malate, Talazoparib Tosylate, Letrozole, CX-2009, SM-88, Neratinib, G1T38, Onapristone, and others
HER2-Negative Breast Cancer Therapeutic Assessment: HER2-Negative Breast Cancer current marketed and HER2-Negative Breast Cancer emerging therapies
HER2-Negative Breast Cancer Market Dynamics: HER2-Negative Breast Cancer market drivers and HER2-Negative Breast Cancer market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
HER2-Negative Breast Cancer Unmet Needs, KOL’s views, Analyst’s views, HER2-Negative Breast Cancer Market Access and Reimbursement

To know more about HER2-Negative Breast Cancer companies working in the treatment market, visit @ HER2-Negative Breast Cancer Clinical Trials and Therapeutic Assessment

Table of Contents

1. HER2-Negative Breast Cancer Market Report Introduction

2. Executive Summary for HER2-Negative Breast Cancer

3. SWOT analysis of HER2-Negative Breast Cancer

4. HER2-Negative Breast Cancer Patient Share (%) Overview at a Glance

5. HER2-Negative Breast Cancer Market Overview at a Glance

6. HER2-Negative Breast Cancer Disease Background and Overview

7. HER2-Negative Breast Cancer Epidemiology and Patient Population

8. Country-Specific Patient Population of HER2-Negative Breast Cancer

9. HER2-Negative Breast Cancer Current Treatment and Medical Practices

10. HER2-Negative Breast Cancer Unmet Needs

11. HER2-Negative Breast Cancer Emerging Therapies

12. HER2-Negative Breast Cancer Market Outlook

13. Country-Wise HER2-Negative Breast Cancer Market Analysis (2019–2032)

14. HER2-Negative Breast Cancer Market Access and Reimbursement of Therapies

15. HER2-Negative Breast Cancer Market Drivers

16. HER2-Negative Breast Cancer Market Barriers

17. HER2-Negative Breast Cancer Appendix

18. HER2-Negative Breast Cancer Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: HER2-Negative Breast Cancer Market and Epidemiology 2032: Treatment Market, Therapies, Companies, FDA Approvals, Epidemiology and Forecast by DelveInsight | Genentech, Inc., AstraZeneca, Novartis

SmartGreenInvest Launches with a Mission to Lead the Net-Zero Carbon Economy

SmartGreenInvest is at the forefront of sustainable finance, driving the shift towards a net-zero carbon economy with its strong focus on ESG principles and responsible investment practices.

LONDON, UK – APRIL 16th, 2024 – SmartGreenInvest, an organization recognized for its forward-thinking approach to sustainable investment and environmental stewardship, aims to accelerate the transition to a net-zero carbon economy by establishing a model for responsible investment practices worldwide.

Image Credits: SmartGreenInvest

SmartGreenInvest’s core objective is to advocate for sustainable practices and spearhead environmental, social, and governance (ESG) initiatives. SmartGreenInvest distinguishes itself from traditional investment paradigms through its strategic focus on reducing carbon footprints, empowering communities, and advocating for environmental protection. The initiative establishes a new standard for corporate accountability by incorporating ESG principles into its comprehensive strategy. Its objective is to achieve a future in which sustainability is an inherent aspect of business operations.

SmartGreenInvest believes that genuine sustainability requires continuous innovation and a firm dedication to achieving high standards. The program aims to make sure that its services are amongst the best by investing in cutting-edge tech, developing talent, and encouraging a growth mindset. By means of innovative approaches or cooperative undertakings, SmartGreenInvest maintains an unshakable commitment to enabling organizations and individuals to recognize sustainability as an essential component of advancement.

Although the path to achieving a net-zero carbon economy is laden with obstacles, SmartGreenInvest is already charting a more environmentally sustainable course. The initiative is leading a paradigm shift toward a more resilient and equitable global community by advocating for systemic reform and promoting sustainable practices at every level. SmartGreenInvest is progressively shaping the course of sustainability through its strategic investments, advocacy efforts, and educational initiatives.

SmartGreenInvest’s actions and decisions are guided by its profound values, which are inextricably linked to its ethos. The initiative is resolute in its pursuit to nurture a global environment conducive to the prosperity of all entities, starting with the promotion of animal welfare and adherence to democratic principles and equality. SmartGreenInvest endeavors to cultivate an all-encompassing and enduring society for future generations by confronting issues of poverty, societal inequalities, and gender discrepancies.

Simply put, SmartGreenInvest represents a shift towards a more promising and sustainable future, surpassing the limitations of traditional finance. SmartGreenInvest is well-positioned to spearhead the transition to a net-zero carbon economy, motivating others to participate in the shared mission of creating a greener and more sustainable world. The company’s strong focus on ESG principles and its drive for innovation and excellence are key factors in its leadership role.

To learn more, please visit – https://www.smartgreeninvest.store/pricing or https://smartgreeninvest.org/

About SmartGreenInvest

SmartGreenInvest is at the forefront of Environmental, Social, and Governance (ESG) initiatives, where it integrates sustainable practices into its operations and spearheads the transition to a net-zero carbon economy. Upholding the highest levels of governance and ethics, promoting sustainability, empowering communities, and protecting the environment are their top priorities. Through the application of modern technology and creative resources, they are able to foster professional development and provide services that are second to none.

Media Contact
Company Name: SmartGreenInvest
Contact Person: Evangelos PAPADOPOULOS
Email: Send Email
State: London
Country: United Kingdom
Website: https://www.smartgreeninvest.store/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: SmartGreenInvest Launches with a Mission to Lead the Net-Zero Carbon Economy

Geographic Atrophy Market and Epidemiology Forecast 2032: Population Data, Drugs, Companies and Competitive Intelligence by DelveInsight | Apellis Pharma, Iveric bio., Belite Bio, NGM Biopharma

The Geographic Atrophy market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Geographic Atrophy pipeline products will significantly revolutionize the Geographic Atrophy market dynamics.

DelveInsight’s “Geographic Atrophy Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Geographic Atrophy, historical and forecasted epidemiology as well as the Geographic Atrophy market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Geographic Atrophy market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.

To Know in detail about the Geographic Atrophy market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Geographic Atrophy Market Insights

Some of the key facts of the Geographic Atrophy Market Report:

The Geographic Atrophy market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
In January 2024, Aviceda Therapeutics has released encouraging top-line results from the first part of a Phase II/III trial investigating its product AVD-104 in individuals with geographic atrophy (GA) linked to age-related macular degeneration (AMD). The study recorded favorable safety and efficacy outcomes three months post-administration of a single dose of AVD-104, an intravitreal glycan-coated nanoparticle. The Phase II SIGLEC trial is a two-part study conducted in the United States (NCT05839041), assessing the safety, pharmacokinetics, and effectiveness of intravitreal AVD-104.
In February 2023, The US FDA approved the NDA for Zimura in geographic atrophy and granted priority review along with a Prescription Drug User Fee Act (PDUFA).
In February 2023, The US Food and Drug Administration (FDA) gave approval to SYFOVRE (pegcetacoplan injection) for treating geographic atrophy secondary to age-related macular degeneration.
In the year 2021, the total prevalent case of Geographic Atrophy was 3,056,205 cases in the 7MM. These cases are expected to grow with a significant CAGR in the study period 2019–2032
In the 7MM, the total diagnosed cases of Geographic Atrophy were 2,822,853 cases in 2021. These cases are expected to grow with a significant CAGR in the study period 2019–2032
Globally, more than 5 million people are affected by Geographic Atrophy. Also, as per the published study by GER group, the global prevalence of Geographic Atrophy is 0.66% in all ages
As per National Institute for Health and Care Excellence (NICE) 2019, the prevalence rate of Geographic Atrophy in the United Kingdom was found to be between 1.3%-6.7%
Key Geographic Atrophy Companies: Apellis Pharmaceuticals, Iveric bio., Belite Bio, NGM Biopharmaceuticals, Novartis, CellCure Neurosciences, and others
Key Geographic Atrophy Therapies: Pegcetacoplan, Zimura, LBS-008, NGM621, PPY988/GT005, OpRegen, and others

Geographic Atrophy Overview

Geographic atrophy (GA) is an advanced form of age-related macular degeneration (AMD), a progressive eye condition affecting the macula, the central part of the retina responsible for sharp, central vision. In GA, there is a gradual loss of retinal pigment epithelial cells and photoreceptors, leading to the formation of distinct areas of retinal degeneration known as “geographic” lesions.

Get a Free sample for the Geographic Atrophy Market Report:

https://www.delveinsight.com/report-store/geographic-atrophy-ga-market

Geographic Atrophy Market

The dynamics of the Geographic Atrophy market are anticipated to change in the coming years owing to the expected launch of emerging therapies and others during the forecasted period 2019-2032.

Geographic Atrophy Epidemiology

Geographic Atrophy Epidemiology Segmentation:

The Geographic Atrophy market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

Total Prevalence of Geographic Atrophy
Prevalent Cases of Geographic Atrophy by severity
Gender-specific Prevalence of Geographic Atrophy
Diagnosed Cases of Episodic and Chronic Geographic Atrophy

Download the report to understand which factors are driving Geographic Atrophy epidemiology trends @ Geographic Atrophy Epidemiological Insights

Geographic Atrophy Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Geographic Atrophy market or expected to get launched during the study period. The analysis covers Geographic Atrophy market uptake by drugs, patient uptake by therapies, and sales of each drug.

The report also covers the Geographic Atrophy Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Geographic Atrophy Therapies and Key Companies

Pegcetacoplan: Apellis Pharmaceuticals
Zimura: Iveric bio.
LBS-008: Belite Bio
NGM621: NGM Biopharmaceuticals
PPY988/GT005: Novartis
OpRegen: CellCure Neurosciences

To know more about Geographic Atrophy treatment, visit @ Geographic Atrophy Medications

Geographic Atrophy Market Drivers

Increasing prevalence rate
Geographic Atrophy Emerging novel treatment options
Patient-friendly Dosage Regimes

Geographic Atrophy Market Barriers

Failure of Investigational
Limited knowledge of Geographic Atrophy
Lack of access to specialists

Scope of the Geographic Atrophy Market Report

Study Period: 2019–2032
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Key Geographic Atrophy Companies: Apellis Pharmaceuticals, Iveric bio., Belite Bio, NGM Biopharmaceuticals, Novartis, CellCure Neurosciences, and others
Key Geographic Atrophy Therapies: Pegcetacoplan, Zimura, LBS-008, NGM621, PPY988/GT005, OpRegen, and others
Geographic Atrophy Therapeutic Assessment: Geographic Atrophy current marketed and Geographic Atrophy emerging therapies
Geographic Atrophy Market Dynamics: Geographic Atrophy market drivers and Geographic Atrophy market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
Geographic Atrophy Unmet Needs, KOL’s views, Analyst’s views, Geographic Atrophy Market Access and Reimbursement

Discover more about therapies set to grab major Geographic Atrophy market share @ Geographic Atrophy market forecast

Table of Contents

1. Geographic Atrophy Market Report Introduction

2. Executive Summary for Geographic Atrophy

3. SWOT analysis of Geographic Atrophy

4. Geographic Atrophy Patient Share (%) Overview at a Glance

5. Geographic Atrophy Market Overview at a Glance

6. Geographic Atrophy Disease Background and Overview

7. Geographic Atrophy Epidemiology and Patient Population

8. Country-Specific Patient Population of Geographic Atrophy

9. Geographic Atrophy Current Treatment and Medical Practices

10. Geographic Atrophy Unmet Needs

11. Geographic Atrophy Emerging Therapies

12. Geographic Atrophy Market Outlook

13. Country-Wise Geographic Atrophy Market Analysis (2019–2032)

14. Geographic Atrophy Market Access and Reimbursement of Therapies

15. Geographic Atrophy Market Drivers

16. Geographic Atrophy Market Barriers

17. Geographic Atrophy Appendix

18. Geographic Atrophy Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Geographic Atrophy Market and Epidemiology Forecast 2032: Population Data, Drugs, Companies and Competitive Intelligence by DelveInsight | Apellis Pharma, Iveric bio., Belite Bio, NGM Biopharma

Registration is Open for the 2024 Jewish Choral Festival Where Singing Takes Center Stage

““The Festival is for anyone who wants to experience the joy of Jewish music,” says Matthew Lazar, Festival Founder and Director. “The participants are multi-generational and include amateur singers, professionals, cantors, conductors, and lovers of Jewish music of all ages.””

Each year, the North American Jewish Choral Festival (NAJCF) attracts hundreds of singers from across the country who enjoy five magical days of a life-changing musical experience by expressing themselves through song. One harmonious choral community is led by renowned conductors creating a melodic tapestry of contemporary, folk, classical, and traditional music. Early bird registration is available through May 1st.

The 35^th annual event will be held from July 14-18, 2024, in Westchester County, New York. Registration is now open, with an early bird discount available through May 1. Festival participants enjoy a variety of uplifting Jewish musical experiences. These include daily community sings; workshops and seminars on a wide range of topics; and evening concerts featuring guest choirs and outstanding performers.

“I have been attending the North American Jewish Choral Festival since 2002. It’s one of the highlights of my year and a great opportunity to participate and to be inspired by all of the music going on around you,” comments Steve Cohen of New York. “I particularly enjoy the instant ensembles, where all festival singers learn and rehearse a musical program which is presented at the end of the Festival. I am always amazed at what can be accomplished in a few days. It is a testament to the power of a group dedicated to a goal, with every individual blending into a whole that is greater than the sum of its parts.”

New for 2024, NAJCF is offering a “Boot Camp” for beginning choral singers and those needing to brush up their skills. This special track will help participants learn to follow a score, understand rhythm, blend with others and more.

Each year, the Festival presents the Hallel V’Zimrah Award to honor individuals who have made important contributions to the world of Jewish music. This year’s honoree is Jack Mendelson, world-renowned cantor and international performer, who is being recognized for his artistry as well as his devotion to the choral music of the synagogue.

According to Barry Brian of California, “The Festival represents my five favorite days of the year. I connect to my Jewish heritage through music and form an emotional bond with hundreds of people to create glorious sound.”

“The Festival is an uplifting experience for people of all denominations who have Jewish connections to come together through their love of music,” adds Sharon Greene of Florida.

“Whether you’re a novice or a pro, you’ll leave with new skills, new music and new friends to cherish from this unique and unforgettable Choral Festival,” concludes Maestro Lazar. Program fees for the 5-day Festival including kosher meals are $1295 (early bird price $1195 through May 1^st). Young people up to age 35 can participate for a price of $900 including hotel accommodation. The North American Jewish Choral Festival is a program of the Zamir Choral Foundation.

To register for this year’s Festival, go to North American Jewish Choral Festival – Zamir (zamirchoralfoundation.org). For more information, visit zamirchoralfoundation.org

About Zamir Choral Foundation

The Zamir Choral Foundation, created by Matthew Lazar, promotes choral music as a vehicle to inspire Jewish life, literacy, and community. The Foundation’s programs include the North American Jewish Choral Festival; HaZamir: The International Jewish Teen Choir; the acclaimed Zamir Chorale; Zamir Noded for young adult singers; Zamir Conducting Fellows to train the next generation of Jewish choral conductors; and the HaZamir Preparatory Program for middle school singers. Matthew Lazar, Founder and Director of the Zamir Choral Foundation, is the leading force of the Jewish choral movement in the US. He has worked with Leonard Bernstein, Zubin Mehta, Elie Wiesel, Theodore Bikel, Dr. Ruth Westheimer, and others. The Zamir Choral Foundation is guided by an expansive vision of vibrant Jewish identity across the generational, denominational, and political continuums through the study and performance of Jewish music at the highest level of excellence.

For more information, visit www.zamirchoralfoundation.org

Media Contact
Company Name: CATHY CALLEGARI PUBLIC RELATIONS INC
Contact Person: Liz Ammirato
Email: Send Email
Phone: 914-299-3882
Address:159 Madison Avenue, Apt. 5J
City: New York
State: NY
Country: United States
Website: www.callprinc.com

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Registration is Open for the 2024 Jewish Choral Festival Where Singing Takes Center Stage

Heroic Game Day Announces the Summer Skills Learning Program that will Reverse the Summer Slide for Every Student that Participates…Guaranteed

America is losing its competitive edge because it continues to fall behind in education. Why not utilize the 8-10 weeks of summer break to create a “summer surge” rather than letting kids and schools suffer from the “summer slide”?

Columbus, OH – The 2023-24 school year is quickly drawing to a close, and students are staring at 8-10 weeks of summer vacation. Will they return to school equipped with new skills and motivated to learn, or will many of them simply fall victim to the “summer slide?”

Summer school comes in different forms, but they are all based on old reteaching models that are costly, intermittent, often perceived as punitive, and, by most measures, ineffective.

“Heroic Game Day is the preferred alternative to grandpa’s remedial summer school,” says Dr. Tom Reed, Co-founder of America’s Heroic School. “The Heroic Skills Summer World Cup is a flexible, online solution that doesn’t require a summer school teacher, a computer lab or even a classroom. With a device and an internet connection, every student can engage in fun, effective skills learning activities for as many days, for as much time per day as they want, anywhere they want.”

When kids want to learn and compete, miraculous things happen. Real learning happens.

“We are so confident students will want to engage and compete with their peers across the state, country and even world, that we guarantee any student who competes in the Heroic Skills Summer World Cup will return to school more motivated and skilled than when they left”, states Scott Dow, President of Heroic Game Day, “If schools are not 100% satisfied with the results, they simply don’t have to pay us.”

Key features include:

Unlimited access to the Heroic Skills Summer World Cup for every student on any device at any time. (For maximum impact, it is strongly encouraged to send students home with their Chromebook for the summer).
Trained “Skills Coaches” who encourage and help the students when they need it.
Real time data tracking of school’s progress on the Heroic Skills Summer World Cup national leaderboard.
Individual “summer report card” detailing student learning progress
Rewards such as chromebooks and tablets for outstanding participants
Extensive PR coverage highlighting student achievements and school innovation.
A first-of-its-kind “Free Market Learning” agreement based solely on student results and satisfaction. It’s simple. At the end of the summer, if the student has participated and there is satisfaction with the results, then payment follows. Otherwise, there is no obligation to pay.
These summer months could very well be the ones that change students’ lives. Heroic Game Day can help make it happen with no additional time or resources required from parents or teachers – just a willingness to step outside the box and see the limitless possibilities.

For more information, please contact Ohio’s Heroic Game Day commissioner and lifelong educator (40 years and counting), Dr. Tom Reed, to enroll and ready to go for the summer.

About Heroic Game Day

Heroic Game Day provides the solution for governments, nonprofits and families that want their children to be productive and prosperous members of society when they grow up. Its kid-driven, game-based skills learning app is powered by selected learning, child management, and training apps that motivate kids and their families to learn how to create wealth, be active and healthy and learn great character, and to control technology rather than it controlling them. Its goal is to enroll 100 million new students over the next 5-10 years – mainly coming from the 7-14-year-old market. Heroic Game Day will become synonymous with helping governments and parents around the world help their kids succeed.

About America’s Heroic School

America’s Heroic School complements traditional public and private schools as a “bolt-on” supplement that delivers academic, social, and healthy deliverables to schools while maintaining their autonomy. It is powered by Heroic Game Day, which has been in the making for the past decade, basically using technology (game-based learning, data-driven intelligence, and blockchain) to connect, engage, and deliver world-leading academic, social, and health results that will retain America’s leadership position in the world. This is an extremely scalable education system that can educate one child with the same effectiveness as it can with a million. We know if a student spends 30 mins per day in the game, they will not only become proficient in the Top 20 critical life skills, but they will also become proficient at their math and reading state tests.

Media Contact
Company Name: OtterPR
Contact Person: Pilar Lewis
Email: Send Email
Address:320 1st Ave N
City: St. Petersburg
State: Florida
Country: United States
Website: OtterPR.com

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Heroic Game Day Announces the Summer Skills Learning Program that will Reverse the Summer Slide for Every Student that Participates…Guaranteed

Hemophilia A Pipeline Assessment 2024: Clinical Trials, FDA Approvals, Therapies and Companies by DelveInsight | Spark Therapeutics, Sigilon Therapeutics, ASC Therapeutics, Pfizer, Sanofi Genzyme, etc

“Hemophilia A Pipeline”

Hemophilia A companies are Spark Therapeutics, Sigilon Therapeutics, ASC Therapeutics, Pfizer, Sanofi Genzyme, Novo Nordisk, Hoffmann-La Roche, Chugai Pharmaceutical, Shire, Pfizer, BioMarin Pharmaceutical, Sinocelltech Ltd, Bayer, Ultragenix pharmaceutical, ApcinteX Ltd, Chia Tai Tianqing Pharmaceutical Group Co., Ltd, Expression Therapeutics, LLC, CSL Behring, ASC Therapeutics, Poseida Therapeutics, Staidson Beijing BioPharmaceuticals, Chia Tai Tianqing Pharmaceutical Group, and others.

(Albany, USA) DelveInsight’s ‘Hemophilia A Pipeline Insight 2024‘ report provides comprehensive global coverage of available, marketed, and pipeline Hemophilia A therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the Hemophilia A pipeline domain.

For Hemophilia A emerging drugs, the Hemophilia A pipeline analysis report provides a 360° view of the therapeutics landscape by development point, product type, route of administration, molecule type, and MOA. The pipeline research covers business opportunities, challenges, future partnerships, strong competitors, and growth strategies.

To know more in detail about Hemophilia A pipeline report, click here: Hemophilia A Pipeline Insight

Key Takeaways from the Hemophilia A Pipeline Report

Over 40+ Hemophilia A pipeline therapies are in various stages of development, and their anticipated acceptance in the Hemophilia A market would significantly increase market revenue.
Leading Hemophilia A companies developing novel drug candidates to improve the Hemophilia A treatment landscape include Spark Therapeutics, Sigilon Therapeutics, ASC Therapeutics, Pfizer, Sanofi Genzyme, Novo Nordisk, Hoffmann-La Roche, Chugai Pharmaceutical, Shire, Pfizer, BioMarin Pharmaceutical, Sinocelltech Ltd, Bayer, Ultragenix pharmaceutical, ApcinteX Ltd, Chia Tai Tianqing Pharmaceutical Group Co., Ltd, Expression Therapeutics, LLC, CSL Behring, ASC Therapeutics, Poseida Therapeutics, Staidson Beijing BioPharmaceuticals, Chia Tai Tianqing Pharmaceutical Group, GeneVentiv Therapeutics, Jiangsu Gensciences, 2seventy bio, Generation Bio, Apitope Technology, and others.
Promising Hemophilia A pipeline therapies in various stages of development include SPK-8011, SPK-8016, BIVV001, AGN-193408, Valoctocogene roxaparvovec, P-FVIII-101, STSP 0601, TQG203, SIG-001, Mim8, PF-07055480, Efanesoctocog alfa, WP 1301, Advate, Recombinate, antihemophilic factor, Eloctate, Hemlibra, Cyklokapron, NovoSeven RT, Xyntha, Humate-P, Hemofil-M, Adynovate, Afstyla, Feiba VH, Kogenate FS, Alphanate, Helixate FS, Autoplex T, Jivi, Nuwiq, Research program: gene therapies, GENV-HEM, Research program: gene editing therapeutics, NX-01, and others.
In June of 2023, BioMarin disclosed that the FDA had granted approval to Roctavian for use as a single-dose therapy in individuals with severe hemophilia A.
In February 2023, the FDA in the United States gave the green light to ALTUVIIIO (efanesoctocog alfa), a replacement therapy for factor VIII, for both adults and children diagnosed with hemophilia A. ALTUVIIIO is prescribed for regular preventive measures, as well as for addressing bleeding incidents when needed, and for managing the perioperative period (surgery) in adults and children suffering from hemophilia A.

Request a sample and discover the recent breakthroughs happening Hemophilia A pipeline landscape: https://www.delveinsight.com/sample-request/hemophilia-a-pipeline-insight-2020

Hemophilia A Overview

Hemophilia is an inherited rare bleeding disorder in which blood does not clot properly because the affected person does not produce enough blood-clotting proteins (clotting factors). Patients who are injured cannot stop bleeding unless these factors are present. The severity of hemophilia symptoms is determined by the level of clotting factors. If the clotting factor level is mildly reduced, the patient may only bleed after surgery or trauma. If the deficiency is severe, one can easily bleed for no apparent reason. Small cuts are not dangerous, but internal bleeding is extremely dangerous for Hemophilia patients. Internal bleeding in the elbows, knees, ankles and other joints is the main concern with this genetic disorder. Internal bleeding can cause organ and tissue damage as well as be potentially fatal.

Hemophilia is classified into several types, including Hemophilia A, Hemophilia B, Hemophilia C, and Von Willebrand disease. Hemophilia is classified based on the presence of clotting factors, such as factor VIII in Hemophilia A and factor IX in Hemophilia B. Screening tests for hemophilia include the Complete Blood Count (CBC), Activated Partial Thromboplastin Time (APTT) Test, Prothrombin Time (PT) Test, Fibrinogen Test, and clotting factor tests.

Hemophilia A Pipeline Therapies and Key Companies

Efanesoctocog alfa: Sanofi
FRSW 107: Jiangsu Gensciences
Mim8: Novo Nordisk
SPK-8016: Spark Therapeutics
OCTA101: Octapharma
FRSW 117: Jiangsu Gensciences
TQG203: Chia Tai Tianqing/Pharmaceutical Group
STSP 0601: Staidson Beijing/BioPharmaceuticals
P-FVIII-101: Poseida Therapeutics

Learn more about the Hemophilia A emerging pipeline therapies @ Hemophilia A Clinical Trials advancements: Hemophilia A Pipeline Insight

Hemophilia A Pipeline Therapeutics Assessment

By Product Type

Monotherapy
Combination Therapy

By Stage

Discovery
Pre-Clinical
Phase I
Phase II
Phase III
Pre-registration

By Route of Administration

Oral
Intravenous
Subcutaneous

By Molecule Type

Small molecules
Gene Therapies
Bispecific antibodies
Recombinant proteins
Fusion Proteins
Coagulants
Blood coagulation factor replacements

Request a sample and discover the recent breakthroughs happening Hemophilia A pipeline landscape: https://www.delveinsight.com/sample-request/hemophilia-a-pipeline-insight-2020

Scope of the Hemophilia A Pipeline Report

Coverage: Global
Key Hemophilia A Companies: Spark Therapeutics, Sigilon Therapeutics, ASC Therapeutics, Pfizer, Sanofi Genzyme, Novo Nordisk, Hoffmann-La Roche, Chugai Pharmaceutical, Shire, Pfizer, BioMarin Pharmaceutical, Sinocelltech Ltd, Bayer, Ultragenix pharmaceutical, ApcinteX Ltd, Chia Tai Tianqing Pharmaceutical Group Co., Ltd, Expression Therapeutics, LLC, CSL Behring, ASC Therapeutics, Poseida Therapeutics, Staidson Beijing BioPharmaceuticals, Chia Tai Tianqing Pharmaceutical Group, GeneVentiv Therapeutics, Jiangsu Gensciences, 2seventy bio, Generation Bio, Apitope Technology, and others.
Key Hemophilia A Pipeline Therapies: SPK-8011, SPK-8016, BIVV001, AGN-193408, Valoctocogene roxaparvovec, P-FVIII-101, STSP 0601, TQG203, SIG-001, Mim8, PF-07055480, Efanesoctocog alfa, WP 1301, Research program: gene therapies, GENV-HEM, Research program: gene editing therapeutics, NX-01, Advate, Recombinate, antihemophilic factor, Eloctate, Hemlibra, Cyklokapron, NovoSeven RT, Xyntha, Humate-P, Hemofil-M, Adynovate, Afstyla, Feiba VH, Kogenate FS, Alphanate, Helixate FS, Autoplex T, Jivi, Nuwiq and others.

Dive deep into rich insights for Hemophilia A emerging therapies and assessment; visit @ Hemophilia A Therapeutic Assessment: https://www.delveinsight.com/sample-request/hemophilia-a-pipeline-insight-2020

Table of Contents

1. Introduction

2. Executive Summary

3. Hemophilia A Overview

4. Hemophilia A Pipeline Therapeutics

5. Late Stage Products (Phase III)

6. Mid Stage Products (Phase II)

7. Early Stage Products (Phase I/II)

8. Preclinical Stage Products

9. Discovery Stage Products

10. Hemophilia A Therapeutic Assessment

11. Inactive Hemophilia A Products

12. Collaborations Assessment- Licensing / Partnering / Funding

13. Hemophilia A Unmet Needs

14. Hemophilia A Market Drivers and Barriers

15. Appendix

16. About DelveInsight

About DelveInsight

DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +91-9650213330
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting/conference-coverage-services

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Hemophilia A Pipeline Assessment 2024: Clinical Trials, FDA Approvals, Therapies and Companies by DelveInsight | Spark Therapeutics, Sigilon Therapeutics, ASC Therapeutics, Pfizer, Sanofi Genzyme, etc

Chronic Lymphocytic Leukemia Market Anticipated to Expand by 2032, as Projected by DelveInsight | Loxo Oncology, Oncternal Therapeutics, Novartis, AstraZeneca, Nurix Therapeutics, Merck

“Chronic Lymphocytic Leukemia Market”

Chronic Lymphocytic Leukemia companies are Loxo Oncology, Oncternal Therapeutics, MingSight Pharmaceuticals, Nurix Therapeutics, Starton Therapeutics, TG Therapeutics, Bristol Myers Squibb, Novartis, Aprea Therapeutics, AstraZeneca, Genor Biopharma, Incyte Corporation, MorphoSys, Astex Therapeutics, Lava Therapeutics, Merck, Celgene Corporation and Others

(Albany, USA) DelveInsight’s “Chronic Lymphocytic Leukemia Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of Chronic Lymphocytic Leukemia, historical and forecasted epidemiology as well as the Chronic Lymphocytic Leukemia market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.

The Chronic Lymphocytic Leukemia market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Chronic Lymphocytic Leukemia market size from 2019 to 2032, segmented by seven major markets. The Report also covers current Chronic Lymphocytic Leukemia treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the Chronic Lymphocytic Leukemia market.

Request for a Free Sample Report @ Chronic Lymphocytic Leukemia Market Forecast

Some facts of the Chronic Lymphocytic Leukemia Market Report are:

According to DelveInsight, Chronic Lymphocytic Leukemia market size is expected to grow at a decent CAGR by 2032.
Leading Chronic Lymphocytic Leukemia companies working in the market are Loxo Oncology, Oncternal Therapeutics, MingSight Pharmaceuticals, Nurix Therapeutics, Starton Therapeutics, TG therapeutics, Bristol Myers Squibb, Novartis, Aprea Therapeutics, AstraZeneca, Genor Biopharma, German CLL Study Group, Incyte Corporation, MorphoSys, Astex Therapeutics, Lava Therapeutics, Celgene Corporation, Merck, and others.
Key Chronic Lymphocytic Leukemia Therapies expected to launch in the market are Lenalidomide, Dexamethasone, Arzerra, Ofatumumab, Bendamustine, Acalabrutinib, Lenalidomide, and others.
Retention rate of acalabrutinib in a non-interventional setting. This is a prospective, multicentre, non-interventional study to collect real-world data on retention rates of Chronic Lymphocytic Leukemia patients prescribed with acalabrutinib in Germany.
CLL2-BAAG is a prospective, open-label, multicenter phase-II trial to evaluate the efficacy and safety of a sequential regimen of debulking with bendamustine followed by induction and maintenance with GA101 (obinutuzumab), acalabrutinib (ACP-196) and venetoclax (ABT-199) in patients with relapsed/refractory CLL.
On March 2024, AstraZeneca announced results of an observational study that prospectively assess acalabrutinib therapy retention of CLL patients one year and 2 years after treatment initiation with acalabrutinib in routine clinical practice. Furthermore, therapy adherence, treatment efficacy, overall survival, and QoL to analyse the possible influence of psychological aspects of the patient-based disease perception, a four-group-segmentation for acceptance and perceived control of the health state will be conducted. Finally, disease-, treatment-, and patient-specific factors possibly affecting therapy retention will be analysed: sociodemographic factors, disease and treatment characteristics, comorbidities, therapy adherence, treatment effectiveness, safety, QoL, and psychological segmentation.
On April 2024, Merck Sharp & Dohme announced results of a Phase 3, Randomized Study to Compare the Efficacy and Safety of Nemtabrutinib Versus Chemoimmunotherapy for Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma without TP53 Aberrations.

Chronic Lymphocytic Leukemia Overview

Chronic Lymphocytic Leukemia (CLL) is a type of cancer that affects the white blood cells, specifically the lymphocytes, which are part of the body’s immune system. Chronic Lymphocytic Leukemia is characterized by the slow and progressive accumulation of abnormal lymphocytes in the blood, bone marrow, and lymph nodes.

The exact cause of Chronic Lymphocytic Leukemia is unknown, but it is associated with certain risk factors such as advanced age, family history of Chronic Lymphocytic Leukemia, and exposure to certain chemicals or radiation. Chronic Lymphocytic Leukemia often presents with no or minimal symptoms in its early stages, and it is often diagnosed incidentally during routine blood tests.

As the disease progresses, symptoms may include fatigue, enlarged lymph nodes, recurrent infections, night sweats, and unintentional weight loss. Chronic Lymphocytic Leukemia is typically a chronic condition, but its progression can vary among individuals. Treatment options for Chronic Lymphocytic Leukemia depend on the stage of the disease, the presence of symptoms, and other factors. Common treatment approaches include watchful waiting, chemotherapy, immunotherapy, targeted therapy, and stem cell transplantation.

Learn more about Chronic Lymphocytic Leukemia treatment algorithms in different geographies, and patient journeys. Contact to receive a sample @ https://www.delveinsight.com/sample-request/chronic-lymphocytic-leukemia-cll-market

Chronic Lymphocytic Leukemia Market

The Chronic Lymphocytic Leukemia market outlook of the report helps to build a detailed comprehension of the historical, current, and forecasted Chronic Lymphocytic Leukemia market trends by analyzing the impact of current Chronic Lymphocytic Leukemia therapies on the market and unmet needs, and drivers, barriers, and demand for better technology.

This segment gives a thorough detail of the Chronic Lymphocytic Leukemia market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Chronic Lymphocytic Leukemia market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the Chronic Lymphocytic Leukemia market in 7MM is expected to witness a major change in the study period 2019-2032.

Chronic Lymphocytic Leukemia Epidemiology

The Chronic Lymphocytic Leukemia epidemiology section provides insights into the historical and current Chronic Lymphocytic Leukemia patient pool and forecasted trends for seven individual major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the Chronic Lymphocytic Leukemia market report also provides the diagnosed patient pool, trends, and assumptions.

Explore more about Chronic Lymphocytic Leukemia Epidemiology @ Chronic Lymphocytic Leukemia Market Dynamics

Chronic Lymphocytic Leukemia Drugs Uptake

This section focuses on the uptake rate of the potential Chronic Lymphocytic Leukemia drugs recently launched in the Chronic Lymphocytic Leukemia market or expected to be launched in 2019-2032. The analysis covers the Chronic Lymphocytic Leukemia market uptake by drugs, patient uptake by therapies, and sales of each drug.

Chronic Lymphocytic Leukemia Drugs Uptake helps in understanding the drugs with the most rapid uptake and the reasons behind the maximal use of new drugs and allows the comparison of the drugs based on Chronic Lymphocytic Leukemia market share and size, which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Chronic Lymphocytic Leukemia Pipeline Development Activities

The Chronic Lymphocytic Leukemia report provides insights into different therapeutic candidates in Phase II, and Phase III stages. It also analyses Chronic Lymphocytic Leukemia key players involved in developing targeted therapeutics.

Request for a sample report to understand more about the Chronic Lymphocytic Leukemia pipeline development activities @ https://www.delveinsight.com/sample-request/chronic-lymphocytic-leukemia-cll-market

Chronic Lymphocytic Leukemia Therapeutics Assessment

Major key companies are working proactively in the Chronic Lymphocytic Leukemia Therapeutics market to develop novel therapies which will drive the Chronic Lymphocytic Leukemia treatment markets in the upcoming years are Loxo Oncology, Oncternal Therapeutics, MingSight Pharmaceuticals, Nurix Therapeutics, Starton Therapeutics, TG therapeutics, Bristol Myers Squibb, Novartis, Aprea Therapeutics, AstraZeneca, Genor Biopharma, Incyte Corporation, MorphoSys, Merck, Astex Therapeutics, Lava Therapeutics, Celgene Corporation, and others.

Learn more about the emerging Chronic Lymphocytic Leukemia therapies & key companies @ https://www.delveinsight.com/sample-request/chronic-lymphocytic-leukemia-cll-market

Chronic Lymphocytic Leukemia Report Key Insights

1. Chronic Lymphocytic Leukemia Patient Population

2. Chronic Lymphocytic Leukemia Market Size and Trends

3. Key Cross Competition in the Chronic Lymphocytic Leukemia Market

4. Chronic Lymphocytic Leukemia Market Dynamics (Key Drivers and Barriers)

5. Chronic Lymphocytic Leukemia Market Opportunities

6. Chronic Lymphocytic Leukemia Therapeutic Approaches

7. Chronic Lymphocytic Leukemia Pipeline Analysis

8. Chronic Lymphocytic Leukemia Current Treatment Practices/Algorithm

9. Impact of Emerging Therapies on the Chronic Lymphocytic Leukemia Market

Table of Contents

1. Key Insights

2. Executive Summary

3. Chronic Lymphocytic Leukemia Competitive Intelligence Analysis

4. Chronic Lymphocytic Leukemia Market Overview at a Glance

5. Chronic Lymphocytic Leukemia Disease Background and Overview

6. Chronic Lymphocytic Leukemia Patient Journey

7. Chronic Lymphocytic Leukemia Epidemiology and Patient Population

8. Chronic Lymphocytic Leukemia Treatment Algorithm, Current Treatment, and Medical Practices

9. Chronic Lymphocytic Leukemia Unmet Needs

10. Key Endpoints of Chronic Lymphocytic Leukemia Treatment

11. Chronic Lymphocytic Leukemia Marketed Products

12. Chronic Lymphocytic Leukemia Emerging Therapies

13. Chronic Lymphocytic Leukemia Seven Major Market Analysis

14. Attribute Analysis

15. Chronic Lymphocytic Leukemia Market Outlook (7 major markets)

16. Chronic Lymphocytic Leukemia Access and Reimbursement Overview

17. KOL Views on the Chronic Lymphocytic Leukemia Market

18. Chronic Lymphocytic Leukemia Market Drivers

19. Chronic Lymphocytic Leukemia Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

About DelveInsight

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting/conference-coverage-services

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Chronic Lymphocytic Leukemia Market Anticipated to Expand by 2032, as Projected by DelveInsight | Loxo Oncology, Oncternal Therapeutics, Novartis, AstraZeneca, Nurix Therapeutics, Merck

Stockroom Unveils Its Exclusive Global Furniture and Home Decor Range Showcasing Superior Craftsmanship and Distinctive Aesthetic Appeal

Stockroom introduces the latest pieces of furniture trends designs versatile and perfect for modern living spaces, dining rooms, home offices, and commercial settings.

Current and fashionable pieces of furniture have been presented by STOCKROOM. The store has a wide range of furniture including but not limited to oak dining tables, chairs, lounge chair, coffee table, lamps, bedroom sets, stools, office chairs, desks, bookshelves and more. It has been in the industry for several years and is committed to providing customers with top-notch furniture that meets their needs and preferences. These pieces are made from the finest materials and are crafted with precision to ensure durability and functionality. With the help of this store, clients can customize their orders to fit their unique style and space requirements. They can request specific sizes, colors, or materials to suit their space and personal style. This sets them apart from other online furniture shops as they prioritize the satisfaction of their customers above all else.

STOCKROOM

The have presented new Industrial furniture Hong Kong trend designs that are versatile and perfect for modern living spaces. These pieces have a unique combination of rustic and modern elements, giving any room a distinct character and style. The raw materials used in these pieces, such as metal and distressed wood, add an industrial charm, while the sleek lines and clean finishes give it a contemporary touch. This combination makes these furniture pieces ideal for both residential and commercial spaces, adding a touch of sophistication to any setting.

The Lounge chairs Hong Kong are a must-have for any living room. They offer maximum comfort and style with their unique designs and high-quality materials. The variety of styles available allows customers to choose the perfect piece that complements their existing furniture or serves as a statement piece in the room. From leather to fabric options, each lounge chair is carefully crafted with attention to detail, ensuring its longevity and comfort. Additionally, the range of colors available allows customers to add a pop of color or stick to neutral tones, depending on their preference.

The various chairs Hong Kong designs provided by STOCKROOM are not only stylish but also provide comfort and support. From dining chairs to office chairs, each piece is designed with ergonomics in mind to ensure proper posture and alleviate any discomfort while sitting for long periods of time. These chairs come in different materials, such as wood, metal, or plastic, giving customers a variety of options to choose from based on their preferences and needs. The sleek and modern design of these chairs adds a touch of elegance to any room, making them not only functional but also aesthetically pleasing.

About STOCKROOM

With a strong commitment to quality and customer satisfaction, STOCKROOM continues to be a leader in the furniture industry. Their extensive collection of stylish and functional pieces, along with their customization options, sets them apart from other online furniture shops. They strive to provide customers with innovative and unique designs that will stand the test of time and enhance any living or working space. Visit their website today to explore their collections and find the perfect furniture pieces for home or office.

Media Contact
Company Name: STOCKROOM
Contact Person: Jojoba
Email: Send Email
Phone: +852 2817 0999
Country: HongKong
Website: http://www.stockroom.com.hk/